ReviewSeminars in oncology2011
Immunologic aspects of hypoplastic myelodysplastic syndrome.
Review in Seminars in oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 52 citations in OpenAlex.
- Combined haploidentical and cord blood transplantation for refractory severe aplastic anaemia and hypoplastic myelodysplastic syndrome.British journal of haematology · 2021Trial
- Immunoexpression of CD34, CD117, and p53 in Hypocellular Bone Marrow Disorders.Journal of laboratory physicians · 2022Article
- Exploring the Potential of Eltrombopag: Room for More?Frontiers in pharmacology · 2022Article
- Bone Marrow Failure Syndromes, Overlapping Diseases with a Common Cytokine Signature.International journal of molecular sciences · 2021Review
- Review
- Outcome of allogeneic hematopoietic stem cell transplantation for hypoplastic myelodysplastic syndrome.International journal of hematology · 2020Article
- Acquired aplastic anemia: Is bystander insult to autologous hematopoiesis driven by immune surveillance against malignant cells?World journal of stem cells · 2020Article
- Deletion of Mouse Setd4 Promotes the Recovery of Hematopoietic Failure.International journal of radiation oncology, biology, physics · 2020Article
- Identification of a metabolic gene panel to predict the prognosis of myelodysplastic syndrome.Journal of cellular and molecular medicine · 2020Article
- Idiopathic aplastic anemia vs hypocellular myelodysplastic syndrome.Hematology. American Society of Hematology. Education Program · 2019Article
- Aging- and Senescence-associated Changes of Mesenchymal Stromal Cells in Myelodysplastic Syndromes.Cell transplantation · 2018Review
- Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes.Haematologica · 2017Article
- Hospital-Based Case-Control Study of MDS Subtypes and Benzene Exposure in Shanghai.Journal of occupational and environmental medicine · 2017Article
- [Optimal cut-off points of CD34 and CD117 in the differential diagnosis between hypocellular myelodysplastic syndrome and aplastic anemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2017Article
- Fanconi Anemia: A DNA repair disorder characterized by accelerated decline of the hematopoietic stem cell compartment and other features of aging.Ageing research reviews · 2017Review
- Bone Marrow Immunity and Myelodysplasia.Frontiers in oncology · 2016Review
- Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes.Haematologica · 2015Article
- Immunological derangement in hypocellular myelodysplastic syndromes.Translational medicine @ UniSa · 2014Article
- Toll-like receptor 7-stimulated tumor necrosis factor α causes bone marrow damage in systemic lupus erythematosus.Arthritis & rheumatology (Hoboken, N.J.) · 2014Article
- Naive T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency.Leukemia · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The pathophysiology of myelodysplastic syndromes (MDS) is multiple, complex, and poorly understood. In some cases of MDS, especially those in which the bone marrow is hypocellular, there is increasing experimental and clinical indication that an immune-mediated damage to hematopoietic precursors and changes in the hematopoiesis-supporting microenvironment contribute to disease development. Increased serum levels of type-1 cytokines, tumor necrosis factor-α (TNF-α), and interferon-γ (INF-γ), and oligoclonal expansion of cytotoxic T cells are observed in human MDS. In some cases, the immunologic attack to the marrow appears to be triggered by MDS-specific antigens, damaging the microenvironment and inducing cell apoptosis especially of normal progenitors. In murine models, dysregulation of osteoprogenitors leads to disrupted hematopoiesis of healthy hematopoietic progenitor and stem cells, eventually resulting in MDS and leukemia. In hypocellular MDS, marrow failure appears to be not only the result of ineffective erythropoiesis of abnormal clones, but also due to inhibition of normal progenitors. Immunosuppressive therapy with cyclosporine, anti-thymocyte globulin, or alemtuzumab may alleviate cytopenias and in some instances induce cytogenetic remission. However, not all patients respond to immunosuppression, and the identification of relevant biomarkers for an immune mechanism is necessary to identify those patients who may benefit from this treatment modality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.